5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $400M | -$36M | 98.7% | -11.3% | -$15M | — | $468M |
| 2024 | $310M | -$51M | 99.1% | -22.7% | $21M | — | $456M |
| 2023 | $249M | -$55M | 99.6% | -23.9% | -$2M | — | $443M |
| 2022 | $174M | -$53M | 99.4% | -29.7% | -$51M | — | $402M |
| 2021 | $4M | -$180M | 100.0% | -4281.2% | -$144M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $107M | $13M | 99.6% | 6.8% | -$16M | — | $453M |
| Dec '25 | $104M | -$30M | 97.4% | -18.8% | -$36M | — | $468M |
| Sep '25 | $104M | -$177000 | 99.5% | -6.9% | -$5M | — | $498M |
| Jun '25 | $98M | -$10M | 98.9% | -15.2% | $26M | — | $488M |
| Mar '25 | $94M | $5M | 99.1% | -3.9% | $137000 | — | $477M |
| Dec '24 | $84M | -$24M | 99.6% | -23.1% | -$18M | — | $456M |
| Sep '24 | $80M | $9M | 99.4% | -10.6% | $20M | $439M | $538M |
| Jun '24 | $75M | -$12M | 97.7% | -21.2% | $23M | $453M | $505M |
| Mar '24 | $71M | -$24M | 99.7% | -37.6% | -$5M | $453M | $833M |
| Dec '23 | — | -$20M | — | — | -$19M | — | $443M |
| Sep '23 | — | $906000 | — | — | $10M | — | — |
| Jun '23 | — | -$17M | — | — | -$1M | — | — |
| Mar '23 | — | -$19M | — | — | $8M | — | — |
How the market has priced IMCR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 4 years, Immunocore Holdings Plc's revenue has grown 214.7% per year. These are computed facts, not advice.
As of FY2025, Immunocore Holdings Plc reported — of total debt against $468M of cash; operating income covered interest expense -3.7×.
In FY2025, gross margin was 98.7%, operating margin -11.3%, and net margin -8.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.